- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12993. [Epub ahead of print]
New viral biomarkers for Hepatitis B: Are we able to change practice?
Höner Zu Siederdissen C1, Maasoumy B1, Cornberg M1,2.
Author information
1
Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
2
German Center for Infection Research (DZIF), Partner Site Hannover, Braunschweig, Germany.
Abstract
The management of chronic hepatitis B virus (HBV) infection is challenged by its varying natural course and its stealthy nature. Not all HBV infected patients will develop complications of infection; however, it is of utmost importance to identify patients who are at risk and require antiviral treatment and/or close surveillance. Hepatic inflammation and quantification of HBV DNA have guided treatment decisions in the last decade and these guided interventions have been shown to reduce liver related complications and death. Data on the quantification of additional HBV markers such as hepatitis B surface antigen (HBsAg), hepatitis B core-related antigen (HBcrAg) and hepatitis B virus RNA (HBV RNA) have accumulated in recent years. Here we review the current evidence of how to use these markers and discuss open issues that require additional research. This article is protected by copyright. All rights reserved.
KEYWORDS:
HBV RNA ; HBV infection; HBcrAg; HBsAg; Nuleos(t)ide analogues; PEG-IFN
PMID:
30187603
DOI:
10.1111/jvh.12993
|
|